BrainStorm’s ALS Treatment NurOwn, Filed Over Protest, Will Get US FDA Panel Review

 
• By Sue Sutter
  
Sailing
Will the FDA's current regulatory flexibility in ALS serve as a tailwind for NurOwn's approval? • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers